@estliz.bsky.social
Reposted
Fresh insights from the Flomics team! 🧬💻
Our new preprint is out:
“Systematic cross-study assessment of RNA-Seq workflows for plasma cfRNA profiling”
Is cfRNA the wild west of protocols? We investigated.
📄 Read it: www.biorxiv.org/cgi/content/...
Our new preprint is out:
“Systematic cross-study assessment of RNA-Seq workflows for plasma cfRNA profiling”
Is cfRNA the wild west of protocols? We investigated.
📄 Read it: www.biorxiv.org/cgi/content/...
Systematic cross-study assessment of RNA-Seq experimental workflows for plasma cell-free transcriptome profiling
Plasma cell-free RNA (cfRNA) is a promising source of non-invasive biomarkers, but its clinical translation is hindered by technical challenges and a lack of protocol standardization, which compromise...
www.biorxiv.org
July 15, 2025 at 8:39 AM
Fresh insights from the Flomics team! 🧬💻
Our new preprint is out:
“Systematic cross-study assessment of RNA-Seq workflows for plasma cfRNA profiling”
Is cfRNA the wild west of protocols? We investigated.
📄 Read it: www.biorxiv.org/cgi/content/...
Our new preprint is out:
“Systematic cross-study assessment of RNA-Seq workflows for plasma cfRNA profiling”
Is cfRNA the wild west of protocols? We investigated.
📄 Read it: www.biorxiv.org/cgi/content/...
Reposted
(1/6)
Happy to present our publication on the potential of palaeoproteomics for phylogenetic applications, which also made it to the cover of GBE’s February issue.
In a nutshell…
Happy to present our publication on the potential of palaeoproteomics for phylogenetic applications, which also made it to the cover of GBE’s February issue.
In a nutshell…
March 3, 2025 at 6:23 PM
(1/6)
Happy to present our publication on the potential of palaeoproteomics for phylogenetic applications, which also made it to the cover of GBE’s February issue.
In a nutshell…
Happy to present our publication on the potential of palaeoproteomics for phylogenetic applications, which also made it to the cover of GBE’s February issue.
In a nutshell…
Reposted
🔬 #Innovació | La start-up de la #UPFBarcelona Flomics Biotech ha desenvolupat un test de sang capaç de detectar 5 tipus de càncer en fase inicial.
🧪 Un estudi amb +1.000 pacients confirma una precisió del 92% en càncer de còlon, pulmó, pròstata, pàncrees i mama.
🧪 Un estudi amb +1.000 pacients confirma una precisió del 92% en càncer de còlon, pulmó, pròstata, pàncrees i mama.
La startup UPF Flomics Biotech ha desenvolupat un test de sang per detectar cinc tipus de càncer en estadis inicials
Un estudi amb més de 1.000 pacients confirma que la biòpsia líquida en sang de Flomics Biotech, basada en biomarcadores d'ARN, és altament precisa, mínimament invasiva i escalable, aconseguint un 92% ...
bit.ly
February 3, 2025 at 11:55 AM
🔬 #Innovació | La start-up de la #UPFBarcelona Flomics Biotech ha desenvolupat un test de sang capaç de detectar 5 tipus de càncer en fase inicial.
🧪 Un estudi amb +1.000 pacients confirma una precisió del 92% en càncer de còlon, pulmó, pròstata, pàncrees i mama.
🧪 Un estudi amb +1.000 pacients confirma una precisió del 92% en càncer de còlon, pulmó, pròstata, pàncrees i mama.